GlassScriptPhysician profile
Justin R Smith
NPI 1134382401
$2,092.25
in general payments reported to CMS, 2019-2025
25 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $107 · 2021: $670 · 2022: $122 · 2023: $60.44 · 2024: $72.93 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $400.99 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $388.59 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $247.10 | 2019-2022 | |
| Abbvie INC. | $175.11 | 2019-2023 | Qulipta |
| Glaxosmithkline, LLC. | $142.75 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $118.34 | 2021 | |
| Stryker Corporation | $84.16 | 2019-2025 | Clottriever Bold Catheter |
| Astellas Pharma US INC | $82.56 | 2019 | |
| Amgen INC. | $70.12 | 2019 | |
| Cordis US Corp. | $67.01 | 2021 | |
| Shire North American Group INC | $42.27 | 2019 | |
| Allergan, INC. | $35.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.91 | 2019 | |
| Hologic Sales and Service, LLC | $28.67 | 2023-2024 | Omni Hysteroscope, Acessa Provu System |
| Depuy Synthes Sales INC. | $27.81 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalpropion Pharmaceuticals LLC | $23.58 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.26 | 2019 | |
| Mml US, INC. | $17.17 | 2023 | Reactiv8 |
| Circassia INC. | $16.16 | 2019 | |
| Abbott Laboratories | $14.66 | 2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $12.69 | 2019 | |
| Medtronic, INC. | $12.61 | 2021 | |
| Merck Sharp & Dohme LLC | $12.51 | 2019 | |
| Pfizer INC. | $11.80 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.